TNF-blockade in patients with advanced hormone refractory prostate cancer.
Diaz
Luis A
LA
The Ludwig Center for Cancer Genetics & Therapeutics at Johns Hopkins, Baltimore, MD 21231, USA. ldiaz1@jhmi.edu
Messersmith
Wells
W
Sokoll
Lori
L
Sinibaldi
Vicki
V
Moore
Sandy
S
Carducci
Michael
M
Eisenberger
Mario
M
D000368:Aged; D000911:Antibodies, Monoclonal / Q000494:pharmacology* / Q000627:therapeutic use*; D019008:Drug Resistance, Neoplasm / Q000187:drug effects*; D006801:Humans; D000069285:Infliximab; D015850:Interleukin-6 / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000378:metabolism
D000911:Antibodies, Monoclonal; D015850:Interleukin-6; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab